Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
复制标题
DOI：
10.1016/j.jtho.2016.07.006
复制
发表时间：
2016-12-01
影响因子：
20.4
通讯作者：
Mio, Tadashi
中科院分区：
文献类型：
--
作者：
Fujita, Kohei;Terashima, Tsuyoshi;Mio, Tadashi
近年来，免疫检查点抑制剂的癌症免疫治疗被认为是治疗癌症的支柱之一。纳武单抗是日本第一个被批准用于肺癌治疗的免疫检查点抑制剂。尽管纳武单抗比细胞毒性药物具有更好的生存获益和更少的不良事件，但它可能产生免疫失调毒性，称为免疫相关不良事件。尽管自身免疫表现是众所周知的免疫相关不良事件，但发展为传染病的情况很少见。在这里，我们报告了一名晚期 NSCLC 患者，该患者在纳武单抗治疗期间肺结核迅速发展，并讨论了潜在机制以及检查点抑制剂治疗期间感染的已知情况。 (C) 2016 年国际肺癌研究协会。由爱思唯尔公司出版。保留所有权利。
Recently, cancer immunotherapy by immune checkpoint inhibitors has been considered one of the pillars for the treatment of cancer. Nivolumab is the first immune checkpoint inhibitor approved for lung cancer treatment in Japan. Although nivolumab has superior survival benefits and fewer adverse events than cytotoxic agents, it can generate dys-immune toxicities, known as immune-related adverse events. Although autoimmune manifestations are well-known immune-related adverse events, the development of infectious diseases is rare. Here, we report on a patient with advanced NSCLC in whom pulmonary tuberculosis developed rapidly during nivolumab treatment and discuss the potential mechanisms as well as what is known about infections during checkpoint inhibitor therapy. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.